Prescribing information

 

   

Information about LUCENTIS and its range of ophthalmic indications.

LUCENTIS is an anti-VEGF with a broad range of ophthalmic indications1

LUCENTIS is approved for the following indications1:

 

Image showing the range of indications for LUCENTIS

LUCENTIS specifically targets VEGF-A to inhibit neovascularisation1–3

VEGF-A plays a key role in the angiogenic cascade, leading to neovascularisation and increased permeability.4–12

Diagram showing how LUCENTIS targets VEGF-A in the angiogenic cascade

Indications1

LUCENTIS 0.5 mg is indicated in adults for:

  • The treatment of neovascular (wet) age-related macular degeneration (AMD)
  • The treatment of visual impairment due to diabetic macular oedema (DMO)
  • The treatment of proliferative diabetic retinopathy (PDR)
  • The treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO)
  • The treatment of visual impairment due to choroidal neovascularisation (CNV).

LUCENTIS 0.2 mg is indicated in preterm infants for:

  • The treatment of retinopathy of prematurity (ROP) with zone I (stage 1+, 2+, 3 or 3+), zone II (stage 3+) or AP-ROP (aggressive posterior ROP) disease.

 

AMD, age-related macular degeneration; AP-ROP, aggressive posterior ROP; BRVO, branch retinal vein occlusion; CNV, choroidal neovascularisation; CRVO, central retinal vein occlusion; DMO, diabetic macular oedema; PDR, proliferative diabetic retinopathy; ROP, retinopathy of prematurity; RVO, retinal vein occlusion; VEGF, vascular endothelial growth factor.

References

  1. LUCENTIS® (ranibizumab) Summary of Product Characteristics, July 2020.
  2. Ferrara N et al. Retina 2006;26(8):859–870.
  3. Steinbrook R. N Engl J Med 2006;355(14):1409–1412.
  4. Aiello LP et al. N Engl J Med 1994;331(22):1480–1487.
  5. Campochiaro PA et al. Mol Vis 1999;5:34.
  6. Dvorak HF et al. Am J Pathol 1995;146(5):1029–1039.
  7. Miller JW. Am J Pathol 1997;151(1):13–23.
  8. Miller JW et al. Am J Pathol 1994;145(3):574–584.
  9. Pe’er J et al. Lab Invest 1995;72(6):638–645.
  10. Spilsbury K et al. Am J Pathol 2000;157(1):135–144.
  11. Kurihara T et al. eLife 2016;5:e14319.
  12. Arden GB et al. Curr Diabetes Rev 2011;7(5):291–304.
LUC20-C030b September 2020.
×

Ask Speakers

×

Medical Information Request

Adverse events should be reported. Reporting forms and information can be found at yellowcard.mhra.gov.uk. Adverse events should also be reported to Novartis via [email protected] or online through the pharmacovigilance intake (PVI) tool at http://www.report.novartis.com/
If you have a question about the product, please contact Medical Information on 01276 698370 or by email at [email protected]